# Clay B. Thorp

> Clay B. Thorp is a Series A investor at Hatteras Venture Partners backing Biotechnology. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners)
- Location: Durham, United States
- Total investments: 14
- Last investment: May 2026
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/clay-thorp-b802bb3

Clay B. Thorp is a General Partner and Co-founder at Hatteras Venture Partners and was a General Partner at Catalysta Partners. He attended Harvard Kennedy School and the University of North Carolina at Chapel Hill.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 43% |
| Health Care | 4 | 29% |
| Therapeutics | 3 | 21% |
| Medical | 2 | 14% |
| Software | 2 | 14% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 36% |
| Seed | 2 | 14% |
| Series B | 2 | 14% |
| Series C | 2 | 14% |
| Funding Round | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CREATE Medicines | Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners. | $122M | Series B | May 14, 2026 |  |
| Ten63 Therapeutics | Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. |  | Venture - Series Unknown | Feb 19, 2026 |  |
| GeneCentric Therapeutics | GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina. | $8M | Series C | Jun 18, 2025 |  |
| CREATE Medicines | Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners. | $73M | Series A | May 18, 2023 |  |
| Ten63 Therapeutics | Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. | $15.9M | Series A | May 02, 2023 |  |
| Rodin Therapeutics | Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros' best-in-class structural biologycapabilities, and a team with deep CNS drug development and company formation experience. Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC). | $27M | Series C | Sep 18, 2017 |  |
| Lysosomal Therapeutics | Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish aunique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. |  | Series A | Feb 03, 2015 |  |
| Clearside Biomedical | Clearside BioMedical, an ophthalmic company, specializes in the research, development, and commercialization of therapeutic products through an ocular microinjection platform that targets the individual compartments of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as the retina, trabecular meshwork,and corneal stroma. The company’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space. Clearside BioMedical was incorporated in 2011 and is based in Atlanta, Georgia. |  | Series B | Sep 02, 2014 |  |
| Lysosomal Therapeutics | Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish aunique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. | $4.8M | Seed | May 12, 2014 |  |
| Curoverse | Curoverse employs open-source software to offer management, computation, and sharing services for genomic and biomedical data. At its core, Curoverse uses a free and open-source system called Arvados that was first developed for the Harvard Personal Genome Project. Arvados is designed to address the unique data management, computation, and sharingrequirements are driven by genomic and biomedical data. |  | Seed | Dec 17, 2013 |  |

10 of 14 investments shown.

## Co-investors
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 4 deals together
- [Newpath Management](https://shizune.co/investors/profile/newpath-management-l-p) — VC Fund, 3 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [Chugai Venture Fund](https://shizune.co/investors/profile/chugai-venture-fund) — VC Fund, 2 deals together
- [Draper Associates](https://shizune.co/investors/profile/draper-associates-2) — VC Fund, 2 deals together
- [GRA Venture Fund](https://shizune.co/investors/profile/gra-venture-fund-llc) — VC Fund, 2 deals together

## About Hatteras Venture Partners

VC Fund · Durham, United States

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

5 contacts available at Hatteras Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Douglas Reed | General Partner | https://shizune.co/investors/profile/douglas-reed |
| Jeff Terrell | General Partner | https://shizune.co/investors/profile/jeff-terrell |
| Myla Lai-Goldman | Venture Partner | https://shizune.co/investors/profile/myla-lai-goldman |
| Christy L. Shaffer | General Partner | https://shizune.co/investors/profile/christy-l-shaffer |
| Clay B. Thorp | General Partner and Co-Founder | https://shizune.co/investors/profile/clay-b-thorp |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Clay B. Thorp invest in?

Clay B. Thorp invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Clay B. Thorp last invest?

The most recent investment recorded for Clay B. Thorp closed in May 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co